Kane Biotech (CVE:KNE) Hits New 1-Year Low – Time to Sell?

Shares of Kane Biotech Inc. (CVE:KNEGet Free Report) hit a new 52-week low on Tuesday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 4000 shares trading hands. The stock had previously closed at C$0.04.

Kane Biotech Stock Up 16.7%

The firm has a market cap of C$5.86 million, a PE ratio of -0.44 and a beta of 0.29. The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39. The business has a fifty day moving average price of C$0.03 and a two-hundred day moving average price of C$0.04.

Kane Biotech Company Profile

(Get Free Report)

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.

Further Reading

Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.